Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company, will have its CEO, Steven Nichtberger, M.D., present at the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023, at 9:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company, will have its CEO, Steven Nichtberger, M.D., present at the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023, at 9:30 a.m. ET. This presentation will be accessible via a live webcast on the company's website, with replays available for 30 days.
The company focuses on developing curative targeted cell therapies for autoimmune diseases, utilizing its CABA™ platform which includes the CARTA and CAART strategies. Key candidates include CABA-201 for lupus nephritis and systemic lupus erythematosus, DSG3-CAART for mucosal pemphigus vulgaris, and MuSK-CAART for MuSK myasthenia gravis. Cabaletta Bio's headquarters are in Philadelphia, PA.
Details
News Market Reaction – CABA
The recorded move for CABA in the trading session of this news was -3.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, April 13, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will present a company presentation at the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20, 2023 at 9:30 a.m. ET.
A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays of the presentation will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in lupus nephritis and systemic lupus erythematosus without renal involvement, and the CAART (Chimeric AutoAntibody Receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform may offer potentially curative therapies for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.